Want to see ATYR full AI Analyst Report?
ATYR Stock Chart & Stats
$0.85
-$0.23(-5.91%)
At close: 4:00 PM EST
$0.85
-$0.23(-5.91%)
Day’s Range― - ―
52-Week Range$0.40 - $7.29
Previous CloseN/A
Volume346.43K
Average Volume (3M)2.25M
Market Cap
$53.38M
Enterprise Value$47.08M
Total Cash (Recent Filing)$66.51M
Total Debt (Recent Filing)$11.70M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Aug 12, 2026EPS Estimate
-0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.73
Shares Outstanding98,051,210
10 Day Avg. Volume1,494,591
30 Day Avg. Volume2,252,195
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.08
Price to Sales (P/S)383.25
P/FCF Ratio-1.17
Enterprise Value/Market Cap0.88
Enterprise Value/Revenue247.79
Enterprise Value/Gross Profit-2.11
Enterprise Value/Ebitda-0.69
Forecast
1Y Price Target
$3.13Price Target Upside267.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.57
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet / Modest LeverageModest debt and positive equity provide structural financial flexibility relative to highly leveraged peers, lowering immediate insolvency risk and supporting continued clinical development. This durability helps the company fund trials or negotiate collaborations before near-term financing becomes necessary.
Regulatory Clarity For Phase 3Clear FDA alignment on direct functional and symptom endpoints materially reduces regulatory ambiguity and informs a targeted Phase 3 design. This structural clarity increases probability of an approvable study, improves planning for patient selection and endpoints, and de-risks long-term development strategy.
Phase 2 Safety And Dose-response SignalsDemonstrated safety and dose-responsive efficacy in a large Phase 2 trial provide durable biological validation for efzofitimod, supporting a rational Phase 3 dosing strategy and potential label strengths. These clinical signals underpin commercial potential across ILD indications and support the broader platform narrative.
Bears Say
High Cash BurnSustained negative operating and free cash flow of this magnitude creates a structural financing need that can force dilutive capital raises or constrain trial execution. Over several months this increases execution risk, limits flexibility on development timelines, and pressures strategic options.
Minimal Revenue & Persistent LossesNear-zero commercial revenue and large recurring losses indicate the company cannot self-fund operations, making it structurally reliant on external financing or partnerships. Persistent losses erode equity over time, increasing dilution risk and potentially limiting investment in pipeline expansion.
Nasdaq Listing/compliance RiskAn active listing deficiency and the prospect of a reverse split create long-term shareholder and liquidity risks, potentially deterring institutional investors and complicating future financings. Listing uncertainty also raises governance and market-access concerns that can impair strategic flexibility.
aTyr Pharma News
ATYR FAQ
What was Atyr Pharma Inc.’s price range in the past 12 months?
Atyr Pharma Inc. lowest stock price was $0.40 and its highest was $7.29 in the past 12 months.
What is Atyr Pharma Inc.’s market cap?
Atyr Pharma Inc.’s market cap is $53.38M.
When is Atyr Pharma Inc.’s upcoming earnings report date?
Atyr Pharma Inc.’s upcoming earnings report date is Aug 12, 2026 which is in 30 days.
How were Atyr Pharma Inc.’s earnings last quarter?
Atyr Pharma Inc. released its earnings results on May 15, 2026. The company reported -$0.11 earnings per share for the quarter, beating the consensus estimate of -$0.132 by $0.022.
Is Atyr Pharma Inc. overvalued?
According to Wall Street analysts Atyr Pharma Inc.’s price is currently Undervalued.
Does Atyr Pharma Inc. pay dividends?
Atyr Pharma Inc. does not currently pay dividends.
What is Atyr Pharma Inc.’s EPS estimate?
Atyr Pharma Inc.’s EPS estimate is -0.12.
How many shares outstanding does Atyr Pharma Inc. have?
Atyr Pharma Inc. has 98,051,210 shares outstanding.
What happened to Atyr Pharma Inc.’s price movement after its last earnings report?
Atyr Pharma Inc. reported an EPS of -$0.11 in its last earnings report, beating expectations of -$0.132. Following the earnings report the stock price went down -9.839%.
Which hedge fund is a major shareholder of Atyr Pharma Inc.?
Currently, no hedge funds are holding shares in ATYR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
aTyr Pharma Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.13 (267.65% Upside)
$3.13 (267.65% Upside)
Blogger Sentiment
Bullish
ATYR Sentiment 70%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 250.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $49.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days <0.1%
Last 30 Days ▼ 2.1%
Last 30 Days ▼ 2.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-89.79%
12-Months-Change
Fundamentals
Return on Equity
-99.87%
Trailing 12-Months
Asset Growth
-18.09%
Trailing 12-Months
Company Description
Atyr Pharma Inc.
aTyr Pharma, Inc., a biopharmaceutical firm established in San Diego, California, in 2005, is dedicated to the discovery and advancement of therapeutic solutions. Operating within the United States, the company's research focuses on pioneering novel immunological pathways to address various medical conditions. Its primary investigational drug, efzofitimod, functions as a selective modulator of NRP2. This compound is currently undergoing a Phase III clinical trial for pulmonary sarcoidosis. Additionally, efzofitimod is being evaluated in a Phase 1b/2a clinical study for the treatment of other interstitial lung diseases (ILDs), including conditions such as chronic hypersensitivity pneumonitis and ILDs linked to connective tissue diseases. Beyond its lead candidate, aTyr Pharma's pipeline features ATYR0101, a fusion protein derived from a domain of aspartyl-tRNA synthetase, which is in preclinical stages of development for combating fibrosis. The company is also progressing with ATYR0750, a domain sourced from alanyl-tRNA synthetase, intended for the management of liver disorders. Furthermore, aTyr Pharma has entered into a strategic collaboration and licensing agreement with Kyorin Pharmaceutical Co., Ltd. This partnership is focused on the development and commercialization of efzofitimod for interstitial lung diseases specifically within the Japanese market.
ATYR Stock 12 Month Forecast
Average Price Target
$3.13
▲(267.65% Upside)
Technical Analysis
XBiotech
―
―
Prelude Therapeutics
―
Context Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
Ownership Overview
2.55% Insiders
26.38% Mutual Funds
<0.01% Other Institutional Investors
66.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---